PARP1 and myotonic dystrophy type 1: In this context, senolytic treatment also decreased the number of SA–β-gal+ cells (Figure 7G) and increased the number of caspase-3+ and PARP+ cells to a similar extent in control and DM1 cells (Figure 7H and Supplemental Figure 7C).